Dusek Doesn't Bar Merck Investors' Claims, 3rd Circ. Hears
Institutional funds claiming Merck & Co Inc. misrepresented clinical trial results for its anti-cholesterol drug Vytorin told the Third Circuit on Tuesday that a recent Eleventh Circuit decision concerning the so-called...To view the full article, register now.
Already a subscriber? Click here to view full article